Skyrizi (risankizumab) is a new biologic for treating psoriasis. The first dose in Canada was injected at Charlton Health. This treatment is given by injection as 2 prefilled syringes starting at week 0, week 4 and then every 12 weeks. It works by blocking IL-23, a cytokine that promotes production of IL-17 in skin cells. The results in achieving complete skin clearance are impressive. This is the second medication in this family of biologics.
We are always proud to be on the front lines with new treatments. Make sure to stay tuned to our #WiseWordsWednesday blog to always be kept in the loop about these new innovations.
Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition that can be very painful and…
As the year comes to a close, we wish you a joyful holiday season filled…
Pulmonary arterial hypertension occurs when there is increased pressure in the small blood vessels that…
Polymyalgia rheumatica (PMR) is an inflammatory condition that causes widespread joint and muscle pain along…
Respiratory Syncytial Virus (RSV) is a common virus that can cause serious lung infections, particularly in…
Health Canada has recently approved Rinvoq (upadacitinib) for adults living with Giant Cell Arteritis (GCA). Rinvoq…